PHM-Exch> Here is why there is a "non-compete" between Novartis and Roche

[Claudio Schuftan]

From: shila kaur <kaur_shila at yahoo.com>
You will find this very interesting!  Please read below.  Courtesy of a
HAIAP partner.

Health Action International Asia Pacific (HAIAP)

------------------------------------------------------------------------------------------------------------------------------------------------------

Ever wondered why Novartis and Roche do not compete?

See the paragraph below

Expectations of structural change and divestments will be reignited by the
Symonds announcement, note analysts at Deutsche Bank. *One particular
conundrum for investors is the 33 percent shareholding that Novartis holds
in its compatriot Roche*. Jimenez has ascribed an intangible value to the
shareholding, which allows the company to have some say in any acquisitions
Roche would choose to make that required the issuance of new shares.
Investors may feel that the money could be spent more effectively
elsewhere, particularly as Novartis' financial stake in Roche is something
of a Vasella heirloom and reminder that the former CEO often talked up the
possibility of a Swiss mega merger.

http://www.firstwordpharma.com/node/1078117
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://phm.phmovement.org/pipermail/phm-exchange-phmovement.org/attachments/20130429/6d0a56ac/attachment.html>